IMC Chicago’s ImmunityBio IBRX Stock Holding History

IMC Chicago’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.85M	Buy	326,000 +68,700	+27%	+$520K	﹤0.01%	2673
2026 Q1	$1.97M	Buy	+257,300	New	+$1.76M	﹤0.01%	2585

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IMC Chicago's IBRX Position: Q2 2026 in Review

IMC Chicago reduced its ImmunityBio (IBRX) stake by 45% in Q2 2026, selling an estimated $334K and leaving 53,011 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #4732.

IMC Chicago first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $745K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

IMC Chicago held 53,011 shares of ImmunityBio worth $464K as of Q2 2026.
IMC Chicago sold 44,137 ImmunityBio shares in Q2 2026, an estimated $334K.
ImmunityBio made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #4732 holding.
IMC Chicago first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
IMC Chicago's ImmunityBio position peaked at $745K in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.